MARKET

MNTA

MNTA

Momenta Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.75
+0.97
+3.37%
After Hours: 29.44 -0.31 -1.04% 16:11 04/09 EDT
OPEN
29.26
PREV CLOSE
28.78
HIGH
30.18
LOW
28.72
VOLUME
1.52M
TURNOVER
--
52 WEEK HIGH
34.83
52 WEEK LOW
9.51
MARKET CAP
3.49B
P/E (TTM)
-10.2055
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MNTA stock price target is 37.38 with a high estimate of 50.00 and a low estimate of 23.00.

EPS

MNTA News

More
  • Stock Market's Next Move
  • Seeking Alpha - Article · 18h ago
  • Hedge Funds Have Never Been This Bullish On Momenta Pharmaceuticals, Inc. (MNTA)
  • Insider Monkey · 2d ago
  • Why Align Technology, Bausch Health, Momenta Pharmaceuticals, and ShockWave Medical Stocks Soared Today
  • MotleyFool.com · 3d ago
  • Momenta Provides Corporate Update Amid COVID-19 Pandemic
  • GlobeNewswire · 04/02 12:30

Industry

Biotechnology & Medical Research
+1.63%
Pharmaceuticals & Medical Research
+0.82%

Hot Stocks

Symbol
Price
%Change

About MNTA

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.
More

Webull offers kinds of Momenta Pharmaceuticals, Inc. stock information, including NASDAQ:MNTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNTA stock news, and many more online research tools to help you make informed decisions.